Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Rina Aharoni. (2013) New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis. Expert Review of Clinical Immunology 9:5, pages 423-440.
Read now
Read now
Articles from other publishers (13)
Xandy Melissa Rodríguez MesaAndrés Felipe Moreno Vergara, Leonardo Andrés Contreras BolañosNatalia Guevara MorionesAntonio Luis Mejía PiñerosSandra Paola Santander González. (2021) Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases. Cannabis and Cannabinoid Research 6:3, pages 196-210.
Crossref
Crossref
Ines Reynoso-Moreno, Silvia Tietz, Erika Vallini, Britta Engelhardt, Jürg Gertsch & Andrea Chicca. (2021) Selective Endocannabinoid Reuptake Inhibitor WOBE437 Reduces Disease Progression in a Mouse Model of Multiple Sclerosis. ACS Pharmacology & Translational Science 4:2, pages 765-779.
Crossref
Crossref
Daniela Calina, Ana Maria Buga, Mihaela Mitroi, Aleksandra Buha, Constantin Caruntu, Cristian Scheau, Abdelhakim Bouyahya, Nasreddine El Omari, Naoual El Menyiy & Anca Oana Docea. (2020) The Treatment of Cognitive, Behavioural and Motor Impairments from Brain Injury and Neurodegenerative Diseases through Cannabinoid System Modulation—Evidence from In Vivo Studies. Journal of Clinical Medicine 9:8, pages 2395.
Crossref
Crossref
Daniel Alonso-Alconada, Francisco José Álvarez, Felipe Goñi-de-Cerio, Enrique Hilario & Antonia Álvarez. (2020) Cannabinoid-mediated Modulation of Oxidative Stress and Early Inflammatory Response after Hypoxia–Ischemia. International Journal of Molecular Sciences 21:4, pages 1283.
Crossref
Crossref
Zhi-Yin Lou, Jie Cheng, Xiao-Rong Wang, Yong-Fei Zhao, Jing Gan, Guo-Yu Zhou, Zhen-Guo Liu & Bao-Guo Xiao. (2018) The inhibition of CB 1 receptor accelerates the onset and development of EAE possibly by regulating microglia/macrophages polarization. Journal of Neuroimmunology 317, pages 37-44.
Crossref
Crossref
John-Mark K. Fitzpatrick & Eric J. Downer. (2017) Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis. Neuropharmacology 113, pages 618-626.
Crossref
Crossref
Henrik Hasseldam, Rune Skovgaard Rasmussen & Flemming Fryd Johansen. (2016) Oxidative damage and chemokine production dominate days before immune cell infiltration and EAE disease debut. Journal of Neuroinflammation 13:1.
Crossref
Crossref
Tadhg Crowley, John F. Cryan, Eric J. Downer & Olivia F. O’Leary. (2016) Inhibiting neuroinflammation: The role and therapeutic potential of GABA in neuro-immune interactions. Brain, Behavior, and Immunity 54, pages 260-277.
Crossref
Crossref
Guy A. Cabral & Melissa Jamerson. 2014. Neuroinflammation and Neurodegeneration. Neuroinflammation and Neurodegeneration
569
587
.
Giancarlo Comi. (2013) Disease-modifying treatments for progressive multiple sclerosis. Multiple Sclerosis Journal 19:11, pages 1428-1436.
Crossref
Crossref
Olaf Stuve & Friedemann Paul. (2013) Progressive multiple sclerosis: desperately seeking remedy. The Lancet Neurology 12:9, pages 840-841.
Crossref
Crossref
Eric J. Downer, Eileen Clifford, Sylvie Amu, Padraic G. Fallon & Paul N. Moynagh. (2012) The Synthetic Cannabinoid R(+)WIN55,212-2 Augments Interferon-β Expression via Peroxisome Proliferator-activated Receptor-α. Journal of Biological Chemistry 287:30, pages 25440-25453.
Crossref
Crossref
David Baker, Gareth Pryce, Samuel J. Jackson, Chris Bolton & Gavin Giovannoni. (2012) The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple Sclerosis and Related Disorders 1:2, pages 64-75.
Crossref
Crossref